Adaptation of the [3H]Hypoxanthine Uptake Assay for In Vitro-Cultured Plasmodium knowlesi Malaria Parasites.
The zoonotic malaria parasite Plasmodium knowlesi has recently been established in continuous in vitro culture. Here, the Plasmodium falciparum [(3)H]hypoxanthine uptake assay was adapted for P. knowlesi and used to determine the sensitivity of this parasite to chloroquine, cycloguanil, and clindamycin. The data demonstrate that P. knowlesi is sensitive to all drugs, with 50% inhibitory concentrations (IC50s) consistent with those obtained with P. falciparum This assay provides a platform to use P. knowlesi in vitro for drug discovery.
Eskitis Institute for Drug Discovery, Griffith University, Queensland, Australia.
Megan S J
MS
Arnold
Eskitis Institute for Drug Discovery, Griffith University, Queensland, Australia.
Jessica A
JA
Engel
Eskitis Institute for Drug Discovery, Griffith University, Queensland, Australia.
Ming Jang
MJ
Chua
Eskitis Institute for Drug Discovery, Griffith University, Queensland, Australia.
Gillian M
GM
Fisher
Eskitis Institute for Drug Discovery, Griffith University, Queensland, Australia.
Tina S
TS
Skinner-Adams
Eskitis Institute for Drug Discovery, Griffith University, Queensland, Australia k.andrews@griffith.edu.au.
Katherine T
KT
Andrews
D000818:Animals; D000962:Antimalarials / Q000494:pharmacology; D002738:Chloroquine / Q000494:pharmacology; D002981:Clindamycin / Q000494:pharmacology; D019271:Hypoxanthine / Q000378:metabolism*; D020128:Inhibitory Concentration 50; D008288:Malaria / Q000503:physiopathology*; D010963:Plasmodium falciparum / Q000187:drug effects / Q000378:metabolism / Q000472:pathogenicity; D016790:Plasmodium knowlesi / Q000187:drug effects / Q000378:metabolism*; D002727:Proguanil / Q000494:pharmacology; D014227:Triazines / Q000494:pharmacology
D000962:Antimalarials; D014227:Triazines; C026009:cycloguanil; D019271:Hypoxanthine; D002981:Clindamycin; D002738:Chloroquine; D002727:Proguanil